Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALKS 
Alkermes Plc (ALKS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALKS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -22.46% | Avg. Invested days 39 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.40B USD | Price to earnings Ratio 15.08 | 1Y Target Price 39.2 |
Price to earnings Ratio 15.08 | 1Y Target Price 39.2 | ||
Volume (30-day avg) 1627938 | Beta 0.58 | 52 Weeks Range 22.90 - 36.45 | Updated Date 03/31/2025 |
52 Weeks Range 22.90 - 36.45 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 23.57% | Operating Margin (TTM) 37.84% |
Management Effectiveness
Return on Assets (TTM) 12.54% | Return on Equity (TTM) 27.9% |
Valuation
Trailing PE 15.08 | Forward PE 19.76 | Enterprise Value 4724283165 | Price to Sales(TTM) 3.47 |
Enterprise Value 4724283165 | Price to Sales(TTM) 3.47 | ||
Enterprise Value to Revenue 3.03 | Enterprise Value to EBITDA 9.55 | Shares Outstanding 162614000 | Shares Floating 153993895 |
Shares Outstanding 162614000 | Shares Floating 153993895 | ||
Percent Insiders 1.45 | Percent Institutions 106 |
Analyst Ratings
Rating 3.86 | Target Price 34.08 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 5 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Alkermes Plc
Company Overview
History and Background
Alkermes Plc was founded in 1987. Initially focused on drug delivery technologies, it has evolved into a biopharmaceutical company developing and commercializing innovative medicines for central nervous system (CNS) diseases and oncology.
Core Business Areas
- Proprietary Products: Development and commercialization of proprietary products, including schizophrenia and bipolar disorder treatments (e.g., Aristada, Lybalvi) and oncology programs.
- Royalty and Manufacturing Revenues: Generating revenues through royalties on products developed using Alkermes' technologies and from manufacturing services.
Leadership and Structure
The company is led by Richard Pops (CEO). The organizational structure includes R&D, commercial, and manufacturing divisions.
Top Products and Market Share
Key Offerings
- Aristada: Aristada is an injectable atypical antipsychotic for the treatment of schizophrenia. Competitors include other long-acting injectable antipsychotics such as Risperdal Consta (JNJ) and Invega Sustenna (JNJ). Alkermes reported $364.8 million in net sales for Aristada in 2023.
- Lybalvi: Lybalvi (olanzapine/samidorphan) is an oral atypical antipsychotic for schizophrenia and bipolar disorder. Competitors include olanzapine alone (Zyprexa, generic) and other atypical antipsychotics like Seroquel (AZN) and Abilify (OTCPK:ABLVF). Alkermes reported $197.8 million in net sales for Lybalvi in 2023.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on developing innovative therapies for unmet medical needs. The CNS market is significant, driven by a growing prevalence of mental health disorders.
Positioning
Alkermes is positioned as a company focused on developing and commercializing differentiated medicines for CNS diseases and oncology. Its competitive advantage lies in its proprietary technologies and established commercial infrastructure.
Total Addressable Market (TAM)
The global schizophrenia and bipolar disorder market is expected to reach $20+ billion. Alkermes aims to capture a significant share of this TAM through its key products Aristada and Lybalvi.
Upturn SWOT Analysis
Strengths
- Proprietary drug development platform
- Established commercial infrastructure
- Strong focus on CNS diseases
- Successful track record of developing and commercializing innovative medicines
Weaknesses
- Reliance on key products
- Competition from larger pharmaceutical companies
- Regulatory risks associated with drug development
- Debt Load
Opportunities
- Expanding product pipeline
- Acquiring or partnering with other companies
- Expanding into new therapeutic areas (e.g., oncology)
- Increasing global market penetration
Threats
- Patent expirations
- Generic competition
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- AZN
- ABBV
- LLY
Competitive Landscape
Alkermes faces competition from larger pharmaceutical companies with more resources. Its success depends on differentiating its products and effectively commercializing them.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Alkermes has experienced revenue growth driven by the commercial success of Aristada and Lybalvi.
Future Projections: Analysts project continued revenue growth driven by increased adoption of Aristada and Lybalvi, and the potential approval of new products in development.
Recent Initiatives: Focus on advancing its pipeline of oncology programs, including nemvaleukin alfa.
Summary
Alkermes is a biopharmaceutical company with a growing focus on CNS disorders and oncology. Its strengths lie in its proprietary technologies and commercial infrastructure, however, it faces competition and regulatory risks. The commercial success of Aristada and Lybalvi is driving revenue growth, and expanding its pipeline will be critical for future success. The negative financial performance is a challenge for Alkermes and will require improvement in the future.
Similar Companies
- JNJ
- AZN
- ABBV
- LLY
Sources and Disclaimers
Data Sources:
- Company 10K Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alkermes Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1991-07-16 | Chairman & CEO Mr. Richard F. Pops | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.alkermes.com |
Full time employees 1800 | Website https://www.alkermes.com | ||
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.